Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference ...

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...